Aetion, the medical evidence software that tracks a drugs’ effectiveness for biopharma companies, insurers, and regulatory bodies, has add $19M as Series B extension from investors that include Johnson & Johnson Innovation Ð JJDC, EDBI, and Greenspring Associates. This brings the total Series B round size to $82M. Founded by Allon Rauer, Jeremy Rassen, and Sebastian Schneeweiss in 2013, Aetion has now raised a total of $93.6M in reported equity funding. AlleyWatch exclusively reported on the first close of Aetion’s Series B round last year.
The AlleyWatch audience is driving progress and innovation on a global scale. With its regional media properties, AlleyWatch serves as the highway for technology and entrepreneurship. There are a number of options to reach this audience of the world’s most innovative organizations and startups at scale including having prominent brand placement in a high-visibility piece like this, which will be read by the vast majority of key influencers in the New York business community and beyond. Find out more here.